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A series of novel peptide N-caps was designed with an emphasis on ease of synthesis and an
abundance of hydrogen bond acceptors. Diﬀerent scaﬀolds based on sugars, cyclic
hydrocarbons, and amino acids are developed with a variety of hydrogen bond acceptors
including esters, carboxyls, amides and a sulfonic acid. The eﬃcient use in solid-phase peptide
synthesis was demonstrated by incorporating the N-caps to a resin-bound model peptide.
Their diﬀerential helix nucleating power in aqueous buﬀer was determined by CD studies.
Increases in peptide helicity to a signiﬁcant extent are observed, leading to a discussion of N-
capping eﬃciency versus ease of synthesis. The potential of the elaborated N-caps for the
reversal of b-sheet to a-helix conformations in the context of ﬁbrillogenesis is discussed.
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INTRODUCTION
The a-helix is the most abundant secondary struc-
ture found in proteins, accounting for almost 30% of
all residues (Barlow and Thornton, 1988) and playing
crucial roles in many biological processes such as
receptor binding (Beck-Sickinger and Jung, 1995,
Motta et al., 1989), DNA binding (Ellenberger et al.,
1992, Tuchscherer et al., 1998), hemolysis (Bernheimer
and Rudy, 1986), antibody recognition (Mutter and
Tuchscherer, 2000) and membrane transport. In prin-
ciple, the bioactivity stemming from a helical region of
a protein should be reproducible through the use of the
smaller, isolated helical sequence itself. However, a
peptide sequence that adopts a helix within a protein
will usually exhibit little or no secondary structure
when excised from the stabilizing short- and long-range
interactions present in the parent protein.
As helical structures are often related to bioactive
conformations, some groups have explored ways of
stabilizing helical conformations by substituting more
helicogenic residues and/or introducing Aspi, Lysi + 4
lactam bridges. For example, it has been shown that
the helical N-terminal fragment of parathyroid hor-
mone PTH(1–11) can be made 3,500 times more
potent by substituting more helicogenic amino acids
at speciﬁc positions (Barazza et al., 2005). However,
such techniques require modiﬁcations to the original,
native sequence, sometimes at the expense of critical
residues that are involved in bioactivity.
An alternative means of increasing helicity in-
volves the use of peptidomimetics known as N-caps
that provide surrogate, stabilizing H-bond acceptors
at the N-terminus of a peptide (a C-cap provides
H-bond donors at the C-terminus). Such Helix-cap-
ping motifs are speciﬁc patterns of hydrogen bonding
and hydrophobic interactions that substitute for the
lacking intrahelical H-bonds provided by the adjacent
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helical turn to satisfy backbone >N–H and >C=O
groups in the initial and ﬁnal turns of the helix. Fur-
thermore, the helix geometry interferes with solvent
access to the amide groups at the N-terminus leaving
the shielded polar groups unsatisﬁed, destabilizing the
molecule considerably. To overcome these constraints
at helix ends, distinct conformational motifs are used
that can provide intramolecular H-bond partners and
maintain the hydrophobic interaction (Aurora and
Rose, 1998). In the search of N-caps for optimal H-
bonding and charge interactions for enhancing the
maximum helicity of isolated peptides in aqueous
solution, the primary goal so far was the need for CD
calibration standards in the form of short to medium-
sized chains of deﬁned length that approach 100%
helicity calibrated from Ncap-corrected experimental
helicities at 222 nm, even though the mechanisms of
helix capping stabilization are not fully understood
yet and the upper limit on cap-induced helicity re-
mains largely unexplored (Maison et al., 2001). While
N-caps have the advantage of not requiring substitu-
tions to the core sequence of a helical peptide, to date,
most of the reported N-caps that have been demon-
strated to increase helicity to a signiﬁcant extent are
synthetically very demanding (Mu¨ller et al., 1993). In
the interest of designing novel N-caps that are both
potent helix nucleators and readily accessible for use
in solid-phase (Merriﬁeld, 1963, Stewart and Young,
1984), liquid-phase (Bayer and Mutter, 1972) and
solution synthesis (Bodanszky, 1984), we report here
on the synthesis and evaluation of a series of com-
pounds so far unexplored as N-caps.
MATERIALS AND METHODS
General
Solvents and reagents were purchased from Fluka or Aldrich,
Buchs, Switzerland and unless stated otherwise, were used without
further puriﬁcation. Fmoc amino acid derivatives and Rink amide
resin were purchased from Novabiochem AG, La¨ufelﬁngen, Swit-
zerland. Alloc protected amino acids were obtained from Isochem,
Vert-le-Petit, France. All amino acid derivatives were used without
further puriﬁcation.
ESI mass analyses were recorded on a Finnigan MAT SSQ
710C electrospray spectrometer. All 1H and 13C NMR spectra were
recorded on a DRX400 Bruker spectrometer at 30 C. Chemical
shifts are reported in ppm downﬁeld from TMS. CD spectra were
recorded on a Jasco J-810 spectropolarimeter with an integration
time of 2s for 0.2 nm steps using an average of ﬁve scans to
obtain each spectrum. All CD spectra were recorded at a peptide
concentration of 10 lM in 10 mM phosphate buﬀer at 0 C and
pH 7 in quartz cells of 1 mm path length. Peptide concentrations
were extrapolated from measurements of UV absorbance at
280 nm of tyrosine and other UV chromophores present.
Peptide Synthesis
The peptide sequence H2N-Ala4-Glu-Ala3-Lys-Ala4-Tyr-Arg-
CONH2 was synthesized on Rink amide resin using Fmoc/tBu
protection and PyBOP activation on an Advanced Chemtech 348
Omega Multiple Peptide Synthesizer. DMF solvent was degassed
with dry nitrogen prior to use. The peptide-resin was then split into
smaller portions to which the diﬀerent N-caps were coupled man-
ually. The peptides were cleaved from the resin by treatment with a
solution of TFA/TIS/H2O/DODT (3,6-dioxa-1,8-octanedithiol)
(95:2:2:1; Teixeira et al, 2002) for two hours and precipitated by
the addition of cold ether. The peptides were puriﬁed by semi-
preparative, reversed-phase HPLC on a Vydac C18 column using
linear gradients of eluent A (0.09% TFA in 90% aqueous
acetonitrile) and eluent B (0.09% TFA in water).
1,2,3,4-tetra-O-acetyl-b-D-glucopyranuronyl-Ala4-
Glu-Ala3-Lys-Ala4-Tyr-Arg-CONH2
(1). 1,2,3,4-tetra-O-acetyl-b-D-glucopyranuronic acid (com-
pound 10, Scheme 1) was prepared from glucuronic acid via the
intermediate glucopyranuronic acid acetic anhydride according
to established procedures (Tosin and Murphy, 2002). 0.056 g
(0.16 mmol, 3 equiv) of 10 was coupled to 100 mg H-(Ala)4-
Glu(OtBu)-(Ala)3-Lys(Boc)-(Ala)4-Tyr(tBu)-Arg(Pbf)-Rink amide
(0.052 mmol) in DMF with PyBOP (0.081 g, 0.16 mmol, 3 equiv)
and DIEA (0.027 ml, 0.16 mmol, 3 equiv) for 2 h. Following a
negative Kaiser test, the peptide was cleaved, precipitated, and
puriﬁed by semi-preparative HPLC (C18, 0 ﬁ 100% A, 30 min)
to give a white powder (C73H114N20O28, MW = 1719.80 g/mol).
Scheme 1. Synthesis of N-caps 1 and 2. (i) Ac2O as solvent, 0.1 eq. I2, 2 h, 0 C. Crystallized from DCM/pentane (60%); (ii) THF/H2O (2/1),
3 h, r.t., quantitative; (iii) Resin bound peptide, PyBOP (3equiv), 10 (3 equiv), DIEA (3equiv), DMF, 3 h.
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ESI-MS: (m/z) 860.80 [(M + 2H)/2]+, 574.32 [(M + 3H)/3]+.
HPLC: Rt = 6.77 (C18, 0 ﬁ 100% A in 12 min).
1,2,3,4-tetra-O-acetyl-b-D-glucopyranuronyl-Pro-
Ala4-Glu-Ala3-Lys-Ala4-Tyr-Arg-CONH2 (2)
1,2,3,4-tetra-O-acetyl-b-D-glucopyranuronic acid (0.056 g,
0.16 mmol, 3 equiv) was coupled to 100 mg H-Pro-(Ala)4-
Glu(OtBu)-(Ala)3-Lys(Boc)-(Ala)4-Tyr(tBu)-Arg(Pbf)-Rink amide
(0.052 mmol) in DMF with PyBOP (0.081 g, 0.16 mmol, 3 equiv)
and DIEA (0.027 ml, 0.16 mmol, 3 equiv) for 2 h. A negative
chloranil test conﬁrmed that the coupling was complete and the
peptide was cleaved, precipitated, and puriﬁed by semi-preparative
HPLC (C18, 10 ﬁ 90% A, 30 min) to give a white powder.
(C78H121N21O29, MW = 1816.92 g/mol). ESI-MS: (m/z) 909.81
[(M + 2H)/2]+, 606.79 [(M + 3H)/3]+. HPLC: Rt = 6.97 (C18,
0 ﬁ 100% A in 12 min).
1,2,3,4,5,6-cyclohexanehexacarboxylic bisanhydride
(12)
1,2,3,4,5,6-cyclohexanehexacarboxylic acid (1 g, 2.87 mmol,
Scheme 2) was suspended in acetyl chloride and stirred at 120 C
in a sealed vessel overnight. Filtration and washing with benzene
and ether gave an oﬀ-white solid (0.73 g, 81%). 1H-NMR:
(DMSO-d6), d (ppm) 3.67 (t, 4H), 3.81 (t, 2H).
13C-NMR:
(DMSO-d6), d (ppm) 171.0 (carboxyl-C), 166.8 (anhydride-C),
37.9, 35.9 (aliphatic-C).
As the product could not be characterized by ESI-MS or
HPLC, a small portion was dispersed in ACN and addition of
excess cyclohexyl amine precipitated a white solid that was col-
lected by ﬁltration, washed with ether, and identiﬁed by ESI-MS as
the biscyclohexylamine adduct (C24H34N2O10, MW = 510.53 g/




Compound 12 (0.16 g, 0.52 mmol, 10 equiv) was added to
100 mg H-(Ala)4-Glu(OtBu)-(Ala)3-Lys(Boc)-(Ala)4-Tyr(tBu)-
Arg(Pbf)-Rink amide (0.052 mmol) in DMF with collidine
(0.090 ml, 0.52 mmol, 10 equiv) and heated to 55 C for 1 h.
Following a negative Kaiser test, the peptide was cleaved, precip-
itated, and lyophilized from 1M (NH)2CO3. Puriﬁcation by semi-
preparative HPLC (C18, 10 ﬁ 60% A, 30 min) gave the desired
peptide as a white powder (C71H108N20O29, MW = 1705.73 g/
mol). ESI-MS: (m/z) 853.85 [(M + 2H)/2]+, 596.38 [(M + 3H)/
3]+. HPLC: Rt = 5.46 (C18, 0 ﬁ 100% A in 12 min).
2,4,5-benzenetricarboxyl-Ala4-Glu-Ala3-Lys-Ala4-
Tyr-Arg-CONH2 (4)
1,2,4,5-benzenetetracarboxylic anhydride (0.14 g, 0.52 mmol, 10
equiv) was added to 100 mg H-(Ala)4-Glu(OtBu)-(Ala)3-Lys(Boc)-
(Ala)4-Tyr(tBu)-Arg(Pbf)-Rink amide (0.052 mmol) in DMF with
DIEA (0.11 ml, 0.52 mmol, 10 equiv). The reaction mixture
gradually became deep red over the course of 1.5 h after which a
Kaiser test was negative. The peptide was cleaved, precipitated, and
lyophilized from 1M (NH4)2CO3. Puriﬁcation by semi-preparative
HPLC (C18, 10 ﬁ 60% A, 30 min) gave the desired peptide as a
white powder (C69H102N20O25, MW = 1611.67 g/mol). ESI-MS:
(m/z) 1612.32 [M + H]+, 806.84 [(M + 2H)/2]+, 538.28
[(M + 3H)/3]+. HPLC: Rt = 6.84 (C18, 0 ﬁ 100% A in 12 min).
Cyclic Peptido-Mimetic-Ala4-Glu-Ala3-Lys-Ala4-Tyr-
Arg-CONH2 (5)
The Cyclic Peptido-Mimetic (CPM) from Hoﬀmann-La
Roche (0.017 g, 0.039 mmol, 1.5 equiv) was coupled to 50 mg H-
(Ala)4-Glu(OtBu)-(Ala)3-Lys(Boc)-(Ala)4-Tyr(tBu)-Arg(Pbf)-Rink
amide (0.026 mmol) in DMF with PyBOP (0.021 g, 0.039 mmol,
1.5 equiv) and DIEA (0.013 ml, 0.078 mmol, 3.0 equiv) for 4 h.
Following a negative Kaiser test, the peptide was cleaved, precip-
itated, and puriﬁed by semi-preparative HPLC (C18, 0 ﬁ 80% A,
30 min) to give the desired peptide as a white powder
(C83H121N23O23, MW = 1808.99 g/mol). ESI-MS: (m/z) 905.34
[(M + 2H)/2]+, 603.82 [(M + 3H)/3]+. HPLC: Rt = 8.39 (C18,
0 ﬁ 100% A in 12 min).
Ac-Cys(SO3H)-Ala4-Glu-Ala3-Lys-Ala4-Tyr-Arg-
CONH2 (6)
Fmoc-Cys(SO3H)-OH•2Na (0.061 g, 0.13 mmol, 2.5 equiv)
was coupled to 100 mg H-(Ala)4-Glu(OtBu)-(Ala)3-Lys(Boc)-
(Ala)4-Tyr(tBu)-Arg(Pbf)-Rink amide (0.052 mmol) in DMF with
PyBOP (0.068 g, 0.13 mmol, 2.5 equiv) and DIEA (0.046 ml,
0.26 mmol, 5 equiv) for 1 h and checked by Kaiser test. Following
Fmoc deprotection and acetylation, the peptide was cleaved,
precipitated, and puriﬁed by semi-preparative HPLC (C18, 10 ﬁ
Scheme 2. Synthesis of N-cap 3; (i) acetyl chloride, 120 C, 18 h, quantitative; (ii) Resin bound peptide, 12 (5 equiv), collidine (10 equiv),
DMF, 1 h; (iii) TFA/TIS/H2O/DODT (95:2:2:1); (iv) Lyophilize from 1.0M (NH4)2CO3.
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60% A, 30 min) to give the desired peptide as a white powder
(C64H105N21O23S2, MW = 1600.78 g/mol). ESI-MS: (m/z)
1601.66 [M + H]+, 800.83 [(M + 2H)/2]+, 534.79 [(M + 3H)/
3]+. HPLC: Rt = 6.62 (C18, 0 ﬁ 100% A in 12 min).
Ac-(cyclo-1–5)-Lys-Ala-Tyr(tBu)-Ala-Asp-OH (13)
Peptide 13 (Scheme 3) was prepared by manual stepwise SPPS
on trityl chloride resin (1.5 mmol/g, 1 g, 1.5 mmol). The coupling
of the ﬁrst residue was eﬀected by adding 1.2 equiv amino acid with
DIEA (4 equiv relative to amino acid) to the resin in DCMwhile all
other couplings were performed using PyBOP/DIEA activation.
After the assembly of the linear peptide was complete, the
aspartic acid and lysine side chains were deprotected by treating the
peptide-resin with Pd(PPh3)4 (0.083 g, 0.075 mmol, 0.05 equiv) and
PhSiH3 (0.9 ml, 7.5 mmol, 5 equiv) in CHCl3 under argon for 2 h.
The resin was then washed with DCM, DMF, and 0.5% diet-
hyldithiocarbamate in DMF. Cyclization was eﬀected on resin
using PyBOP (1.17 g, 2.25 mmol, 1.5 equiv) and DIEA (0.51 ml,
3.0 mmol, 2 equiv) in NMP for 4 h after which a Kaiser test was
negative. Cleavage was achieved with a mixture of AcOH/TFE/
DCM 10:20:70, 2 1 h. Removal of solvent in vacuo and puriﬁ-
cation by semi-preparative HPLC (C18, 0 ﬁ 75% A, 30 min)
yielded the desired peptide (C31H46N6O9, MW = 646.73 g/mol).
ESI-MS: (m/z) 647.64 [M + H]+. HPLC: Rt = 4.57 (C18, 0 ﬁ
100% A in 10 min).
Ac-(cyclo-1–5)-Lys-Ala-Tyr-Ala-Asp-Ala4-Glu-Ala3-
Lys-Ala4-Tyr-Arg-CONH2 (7)
Ac-[(cyclo-1–5)-Lys-Ala-Tyr(tBu)-Ala-Asp]-OH 13 (0.084 g,
0.13 mmol, 2.5 equiv) was coupled to 100 mg H-(Ala)4-Glu-(Ala)3-
Lys-(Ala)4-Tyr-Arg-Rink amide (0.052 mmol) in DMF with
PyBOP (0.068 g, 0.13 mmol, 2.5 equiv) and DIEA (0.023 ml,
0.13 mmol, 2.5 equiv) for 2 h and checked by Kaiser test. The
peptide was cleaved, precipitated, and puriﬁed by semi-preparative
HPLC (C18, 0 ﬁ 80% A, 30 min) to give the desired peptide as a
white powder (C86H134N26O26, MW = 1948.14 g/mol). ESI-MS:
(m/z) 974.86 [(M + 2H)/2]+, 650.32 [(M + 3H)/3]+. HPLC:
Rt = 7.08 (C18, 0 ﬁ 100% A in 12 min).
RESULTS AND DISCUSSION
The choice of peptide sequence for the evaluation
of N-cap eﬃciency is critical as earlier studies report
very wide ranges of increases in helicity, with larger
increases typically reported for sequences that were
already weakly helical or shorter in length. Therefore,
for the direct comparison of the helix inducing eﬃ-
ciency of diﬀerent N-caps, a previously designed
system, the alanine-rich model peptide H2N-Ala4-
Glu-Ala3-Lys-Ala4-Tyr-Arg-CONH2 was chosen
(Forood et al., 1994). The arginine serves as the C-
capping residue, the tyrosine at position 14 permits
UV quantitation, and glutamic acid and lysine resi-
dues at positions 5 and 9 respectively are ideally
located to form an intrahelical salt bridge and thus,
increase overall solubility.
The design of possible N-caps was based on two
primary principles. Firstly, the N-cap should possess
numerous hydrogen bonding acceptors including a
carboxyl or anhydride group suitable for the attach-
ment to the N-terminus of a peptide and, secondly, it
should be straightforward to synthesize.
Figure 1 displays the N-cap candidates in their
peptide-conjugated form that were investigated, none
of which have been previously explored as potential
N-caps except for compound 54 (Mu¨ller et al., 1993).
Sugars oﬀer the potential for readily available
scaﬀolds that can present ﬁve or more hydrogen
bond acceptors upon peracetylation. While there are
numerous publications on the eﬀects of attached
Scheme 3. Synthesis of N-cap 7; (i) Fmoc/tBu SPPS; (ii) Pd(PPh3)4 (0.5 equiv), PhSiH3 (10 eqiv), TIS (10 equiv), CHCl3, N2, 2 h; (iii) PyBOP
(1.5 equiv), DIEA (3equiv), NMP, 4 h; (iv) DCM/TFE/AcOH (70/20/10), 2 h; (v) Resin bound peptide, PyBOP (2.5 equiv), 13 (2.5 equiv),
DIEA (2.5 equiv), DMF, 2 h; (vi) TFA/TIS/H2O/DODT (95:2:2:1), 2 h.
4Compound 5 was a generous gift from Prof. Klaus Mu¨ller,
Hoﬀmann-La Roche, Basel.
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sugars on peptide conformation (Bosques et al.,
2004), (Otvos and Cudic, 2003), the use of sugar-
derived molecules as possible N-caps remains
unexplored. For example, peracetylation of b-D-
glucuronic acid with iodine catalyst followed by
liberation of the carboxyl group yielded glucopy-
ranuronic acid (compound 10, Scheme 1) that was
soluble in organic solvents (Tosin and Murphy,
2002). This product was readily coupled to the model
peptide by standard solid-phase peptide synthesis
(SPPS) to give N-capped peptide 1 (Scheme 1). Based
on the fact that proline residues are found to support
helix formation when found near the N-termini (Pal
et al., 2003) for the N-capped peptide 2 the peptide
sequence was further extended by one proline residue
on solid phase prior to coupling the sugar derivative
10. N-caps 3 and 4 are derived from cyclic poly-
carboxylic acids that are subsequently converted to
the corresponding acid anhydrides. The anhydrides
are reacted with the N-terminus of the peptide. After
completion of the coupling, the remaining anhydrides
are hydrolysed to the carboxyl groups during the
cleavage of the peptide from the resin as depicted in
Scheme 2. The peptide was further treated with base
to drive the hydrolysis to completion, ideally with
ammonium carbonate as it is removed during
lyophilization. The resulting N-caps bear several
carboxyl groups, each of which can potentially en-
gage in hydrogen bonding with two peptidic amide
groups. In more detail, the anhydride of N-cap 3 is
obtained by heating 1,2,3,4,5,6-cyclohexanehexa-
carboxylic acid in acetyl chloride at 120 C in a sealed
vessel overnight (Betnev et al., 1999). The anhydride
of N-cap 4, 1,2,4,5-benzene tetracarboxylic anhy-
dride, is commercially available. The above acylation
strategy was successfully used to introduce N-caps 3
and 4. In a study of N-capping groups containing a
sulphur atom in various oxidation states, the sulfonic
acid moiety turned out to be the most a-helix stabi-
lizing N-cap (Forood et al., 1994). This unit was
introduced at the N-terminus of the peptide by cou-
pling of S-trityl-3-mercaptopropionic acid. After
cleavage of the peptide from the resin and puriﬁca-
tion, the thiol group was oxidized with performic acid
to give the sulfonic acid. In contrast, for the synthesis
of N-capped peptide 6, the coupling of the disodium
salt of Fmoc-Cys(SO3H)-OH, which is commercially
available from Bachem (Bubendorf, Switzerland),
Fig. 1. N-cap candidates in their peptide-conjugated form.
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provides a straightforward means for introducing a
sulfonic acid moiety to a peptide by standard PyBOP
activated coupling methods. After completion of the
reaction, the Fmoc protection was removed and the
terminal NH2-group acetylated. N-cap 7 consists of a
pentapeptide containing aspartic acid and lysine res-
idues at positions i and i + 4 respectively. Orthogo-
nal allyl-based protection of the Lys and Asp side
chains allows for selective Pd-catalysed deprotection
and subsequent on-resin cyclization via a lactam
bridge (Scheme 3). This eﬀectively constrains the
residues into an enforced a-helical turn and, when
incorporated into a larger peptide, can greatly
increase the overall helicity (Felix et al., 1988). The
Fairlie group recently reported a method of synthe-
sizing protected lactam-bridged pentapeptide frag-
ments that could be used as building blocks in SPPS
(Shepherd et al., 2004). The peptide is constructed
and cyclized on a highly acid labile support. Cleavage
under mildly acidic conditions results in a fully
protected peptide fragment with a free acid at the
C-terminus, suitable for further coupling to a resin
bound peptide by standard SPPS methodologies.
Table I summarizes the results obtained with the
series of N-caps and Fig. 2 shows some of the
corresponding CD spectra of the N-capped
peptides. The peptide sequence lacking the N-cap
(N-cap = H) is only weakly helical (18%) while
acetylation of the N-terminus leads to an increase in
helicity of up to 32% as reported in literature (Forood
et al., 1994). However, all N-caps listed in Table 1
containing multiple hydrogen bond acceptors induce
signiﬁcant increases in the overall helicity compared
to the uncapped or acetylated peptide.The least eﬃ-
cient are the sugar based N-caps 1 and 2. It is possible
that the acetyl groups do not adopt a low energy
conformation to serve as H-bond acceptors being
crucial for a helix stabilizing potential. However,
given the large number of diﬀerent sugars available
exposing alternative orientations of the acetyl groups
in space, the use of sugar based molecules as N-caps
might best be explored by combinatorial techniques
(Le et al., 2003). From the perspective of helix
inducing power versus ease of synthesis, N-cap 4
seems the best choice. Two steps, i.e. acylation of the
peptide with 1,2,4,5-benzene tetracarboxylic anhy-
dride and following hydrolysis of the remaining
anhydride, lead to an increase in peptide helicity from
17% to 70%. It is important to note, that even though
both N-caps 3 and 4 contain multiple, ionisable car-
boxyl groups, their inﬂuence on the helicity of the
model peptide was found to be pH-independent in the
range of 2–10. The cyclic pentapeptide N-cap 7 as
well as the tetrahydronaphthalene based N-cap 5
proved to be the most eﬃcient helix nucleators (86%
and 89% helicity). While the observed [h]222 values of
both molecules are very close, the course of the CD
spetrum of N-cap 7 shows additional characteristics
that indicate greater helicity (Fig. 2). Firstly, the zero
transition is at 201 nm, consistent with literature
values for helix standards (Fasman, 1996). Secondly,
the [h]222/[h]208 ratio is equal to 1.2, a value close to
that recently proposed by the Kemp group (ratio of
1.3) for alanine-rich peptides adopting a complete
helical conformation (Heitmann et al., 2005), espe-
cially at lower temperatures (Job et al., 2006). N-cap
5, however, also produced a high degree of helicity
(89%) when the contribution of the amino acid
residues forming the N-cap were neglected in the
Table I. Summary of helix contents of N-cap-Ala4-Glu-Ala3-Lys-
Ala4-Tyr-Arg-CONH2. Percent helicity is calculated as 100
([h]222/
max[h]222), where [h]222 is the mean residue ellipticity value at
222 nm and max[h]222 is the theoretical maximum possible value gi-
ven by the formula max[h]222 = )40,000[1)(2.5/n)] (Scholtz et al.,
1991). The variable n refers to the number of amino acid residues in
the peptide being measured and the value )40,000 deg Æ cm2 Æ dmol)1
is the value used for the inﬁnite helix (n = ¥) (Chen et al., 1974).
Percent helicity was independent of peptide concentration in the








No N-cap 6,100 15 18
1 18,100 15 54
2 15,100 16 45
3 20,000 15 62
4 23,300 15 70
5 29,700 15 89
6 16,500 16 49
7 30,100 20 86
Fig. 2. CD curves of peptides N-cap-Ala4-Glu-Ala3-Lys-Ala4-Tyr-
Arg-NH2 with selected N-caps at 1.0 10)5M in pH 7 phosphate
buﬀer at 0 C.
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calculation of the helix content. Though it is very
eﬀective at nucleating helical structure, the synthesis
of this scaﬀold is very complex and involves more
than forty steps (Mu¨ller et al., 1993).
OUTLOOK
The present investigation represents a ﬁrst, sys-
tematic comparison of a series of readily accessible
N-caps that diﬀer widely in the number, orientation,
and type of hydrogen bond acceptors, some scaﬀolds
generating an increase in helicity up to 4-fold with
respect to the uncapped peptides. In general, the
overall induced ellipticity values of the diﬀerent
N-caps presented do not vary greatly, but the data
obtained clearly demonstrate the potency of the helix
inducing eﬀect of N-caps in comparison with the
uncapped peptides. The scope of the present paper
was not the design and/or optimisation of ideal N-
cap candidates rather a ﬁrst evaluation of syntheti-
cally easily accessible molecules with a pronounced
helix inducing power. From this point of view the
cyclic peptide N-cap 7 appears as the most promising
candidate due to its potential structural variability
and ease of synthesis even amenable to combinatorial
approaches.
Continuing advances in the rational design and
optimisation of helix inducing N- and C-caps may
eventually obviate the need to alter a peptides core
sequence with nonnative residues or peptidomimetics
in order to increase its overall helicity. Most notably,
N-caps may play a crucial role in reversing aggre-
gated b-sheet assemblies of peptides to helical states
as relevant in ﬁbrillogenesis as origin of degenerative
diseases. Preliminary studies for the use of N-caps to
transform b-sheet- and ﬁbril-forming Ab-derived
peptides to helical structures in situ applying the
concept of switch-peptides (Fig. 3, Mutter et al.,
2004) conﬁrm the potential of this approach for
therapeutic applications (Mimna et al., 2006).
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